Table 2.
Pharmacokinetic characteristics after acute metformin dosing
| Intolerant group Median (IQR) | Tolerant group Median (IQR) | Geometric mean ratio (95% CIs) | P value (unpaired t test) | |
|---|---|---|---|---|
| AUC, mg/L*h | 13.9 (12.9‐16.8) | 16.9 (13.9‐18.6) | 0.95 (0.72‐1.26) |
.72 |
| Cmax, mg/L | 2.0 (1.8‐2.2) | 2.1 (1.7‐2.3) | 1.04 (0.83‐1.30) |
.76 |
| T1/2, h | 4.1 (3.8‐4.3) | 4.8 (4.7‐5.3) | 0.82 (0.76‐0.89) |
<.001 |
| CL/F, L/h | 35.2 (29.4‐38.1) | 28.6 (25.8‐34.6) | 1.07 (0.81‐1.43) |
.62 |
| V/F, L | 211.4 (164.0‐225.8) | 197.3 (186.0‐261.3) | 0.88 (0.66‐1.17) |
.36 |
| CLr, L/h | 17.6 (13.9‐25.5) | 20.5 (14.7‐25.2) | 0.88 (0.56‐1.41) |
.59 |
| F, % | 71 (62‐84) | 95 (56‐101) | 0.83 (0.53‐1.27) |
.38 |
Abbreviations: CL/F, apparent total clearance from plasma after oral administration; CLr, renal clearance of the drug from plasma; F, estimated bioavailability; V/F, volume of distribution.